Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 2/20 | 0.52 |
| ▸ | HRH1 | P35367 | 2/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 16/20 | 0.47 |
| ▸ | DRD2 | P14416 | 15/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4064111 | 1.00 | HRH2 (0.52) | HRH2HRH1ROCK2DRD3DRD2 | |
| SCHEMBL4072122 | 0.84 | DRD2 (0.49) | HRH2HRH1DRD3DRD2 | |
| SCHEMBL4072112 | 0.84 | DRD2 (0.49) | HRH2HRH1DRD3DRD2 | |
| SCHEMBL4070514 | 0.81 | DRD3 (0.49) | DRD3DRD2 | |
| SCHEMBL4070512 | 0.81 | DRD3 (0.49) | DRD3DRD2 | |
| SCHEMBL4075484 | 0.80 | DRD3 (0.53) | DRD3DRD2 | |
| SCHEMBL4075490 | 0.80 | DRD3 (0.53) | DRD3DRD2 | |
| SCHEMBL4067934 | 0.78 | DRD2 (0.57) | DRD3DRD2 | |
| SCHEMBL4067938 | 0.78 | DRD2 (0.57) | DRD3DRD2 | |
| SCHEMBL4065555 | 0.77 | DRD2 (0.44) | DRD3DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725240-A4 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-03-25 | — | — | EP | claimed |
| US-20070185090-A1 | Muscarinic acetylchoine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
| EP-1725240-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-29 | — | — | EP | claimed |
| WO-2005094834-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-10-13 | — | — | WO | claimed |
| EP-1725240-A4 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-03-25 | — | — | EP | disclosed |
| US-20070185090-A1 | Muscarinic acetylchoine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1725240-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005094834-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185090-A1 | Muscarinic acetylchoine receptor antagonists | CHRM3, CHRNG, CHRM2 | HRH2 132/4885HRH1 253/4885ROCK2 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.